Digital Pathology System began to cooperate with one of largest pathomorphology laboratories of Europe – Boipticka Laborator s.r.o. The Digital Pathology platform for telemedicine consulting was highly appreciated by many pathologists from Russia, the United States, Great Britain and Germany. The high quality of images of histopathology sections is emphasized by specialists who consult cases in different cities of Russia and foreign countries. The number of pathologists collaborating with the System grows rapidly, which leads to increasing competence of the specialists and to the development of connections among the doctors practicing in different countries.
It is necessary to underline that the Digital Pathology service is not only focused on the cooperation with individual pathologists – the UNIM LTD. company continues to expand cooperation with high-tech laboratories all over the world. Biopticka laborator s.r.o., the second largest pathomorphology laboratory in Europe, has recently joined the SAAS-platform.
Biopticka laborator s.r.o. is the largest biopsy and cytology laboratory in the Czech Republic. It performs 800,000 gynecological examinations annually, so it is one of the largest cytology laboratories in the world. Biopticka laborator s.r.o. employs internationally recognized experts, who are regularly published in top international journals, and who are invited as speakers to the European, American and world congresses. Biopticka laborator s.r.o. offers examinations of gynecological cytology (oncological and functional examination of smears from the cervix, vaginal, vulvar and endometrial mucosa) and non-gynecological cytology, biopsy, as well as complete biopsy service with a direct connection to any necessary immunohistochemical and molecular genetic testing.
Biopticka laborator s.r.o. is accredited by ČIA (Czech Institute for Accreditation) under ČSN EN ISO 15189 and holds accreditation of Ministry of Health for cervical cancer screening. The Association of health insurance companies has chosen the Biopticka laborator s.r.o. as one of the few laboratories in the Czech Republic for the program of predictive oncology, that have approved the genetic performances in pathology, such as examination of HER2/neu in breast cancer, as well as KRAS mutation of cancer of the colon and rectum.
Almost all the available funds of laboratory are reinvested in its own research, particularly in molecular genetic methods. Bioptická laboratoř s.r.o. publishes extensively. Over the last ten years of existence of the Bioptická laboratoř s.r.o., their doctors have published nearly 700 publications in top world international impacted journals (see our publications) and almost 300 articles in Czech professional journals. Almost half of the scientific articles have been published in the best American professional pathology journals.